{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=26", "query": { "condition": "Phase 2 Study", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 17251, "total_pages": 1726, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T02:56:45.970Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03223610", "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Revlimid (lenalidomide)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 155, "start_date": "2018-02-09", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03223610" }, { "nct_id": "NCT01285310", "title": "Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Apremilast 30 mg", "type": "DRUG" }, { "name": "Apremilast 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2010-12-09", "completion_date": "2012-09-10", "has_results": true, "last_update_posted_date": "2020-05-08", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 29, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285310" }, { "nct_id": "NCT00157560", "title": "Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Chemotherapy, multiple agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 83, "start_date": "2000-12", "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2008-01-03", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00157560" }, { "nct_id": "NCT01856920", "title": "QUILT-3.006 for Recurrent Medullary Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medullary Thyroid Cancer (MTC)" ], "interventions": [ { "name": "GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NantCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 35, "start_date": "2013-03-26", "completion_date": "2018-05-08", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856920" }, { "nct_id": "NCT01330979", "title": "24-hour Efficacy of AR-12286", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Open Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "AR-12286 0.5% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerie Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 5, "start_date": "2011-05", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330979" }, { "nct_id": "NCT02899988", "title": "A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Mirikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 205, "start_date": "2016-09-14", "completion_date": "2019-05-08", "has_results": true, "last_update_posted_date": "2020-06-18", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 12, "location_summary": "Ocala, Florida • Tampa, Florida • Plainfield, Indiana + 9 more", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02899988" }, { "nct_id": "NCT00227591", "title": "Lenalidomide and Prednisone in Treating Patients With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Essential Thrombocythemia", "Polycythemia Vera", "Primary Myelofibrosis" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-12", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2014-05-21", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227591" }, { "nct_id": "NCT02326974", "title": "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER-2 Positive Breast Cancer", "Breast Cancer", "Stage II Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "T-DM1", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Excision of tumor/mastectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2015-01", "completion_date": "2028-01", "has_results": true, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326974" }, { "nct_id": "NCT06383390", "title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerotic Cardiovascular Disease (ASCVD)", "Chronic Kidney Disease (CKD)" ], "interventions": [ { "name": "Retatrutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 10000, "start_date": "2024-04-30", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 204, "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06383390" }, { "nct_id": "NCT00229723", "title": "IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Squamous Cell" ], "interventions": [ { "name": "Gefitinib (Iressa)", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2004-11", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2009-08-04", "last_synced_at": "2026-10-22T02:56:45.970Z", "location_count": 2, "location_summary": "Aurora, Colorado • Dallas, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00229723" } ] }